Back to Search
Start Over
The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome.
- Source :
-
Diabetes, obesity & metabolism [Diabetes Obes Metab] 2008 Jun; Vol. 10 (6), pp. 476-83. Date of Electronic Publication: 2007 Apr 24. - Publication Year :
- 2008
-
Abstract
- Objective: We assessed the effect of orlistat and fenofibrate, alone or in combination, on plasma high-density lipoprotein (HDL) subfractions and plasma pre-beta1-HDL levels in overweight and obese subjects with metabolic syndrome (MetS).<br />Methods: Patients (n = 89) were prescribed a low-fat low-calorie diet and were randomly allocated to receive orlistat 120 mg three times daily (O group), micronized fenofibrate 200 mg/day (F group) or both (OF group) for 6 months. HDL subfractions were determined using a polyacrylamide gel tube electrophoresis method and pre-beta1-HDL levels using enzyme-linked immunoabsorbent assay.<br />Results: We observed a significant change of high-density lipoprotein cholesterol (HDL-C) levels only in the F group (+3%, p < 0.05). Large HDL-C levels were significantly increased and small HDL-C levels were significantly reduced with O administration. In F group we observed a significant increase of small HDL-C levels. No significant change of large or small HDL-C levels was observed with combination treatment. We observed a significant increase of pre-beta1-HDL levels in all groups, which was significantly greater in OF group compared with O or F monotherapy.<br />Conclusion: OF combination increased the antiatherogenic pre-beta1-HDL levels in overweight and obese patients with MetS. Furthermore, OF combination counterbalanced the reduction of small HDL-C levels observed with orlistat monotherapy.
- Subjects :
- Anti-Obesity Agents pharmacology
Body Mass Index
Cholesterol, HDL blood
Cholesterol, HDL drug effects
Drug Therapy, Combination
Female
Fenofibrate pharmacology
Greece
High-Density Lipoproteins, Pre-beta blood
High-Density Lipoproteins, Pre-beta drug effects
Humans
Hypolipidemic Agents pharmacology
Lactones pharmacology
Lipoproteins, HDL drug effects
Male
Metabolic Syndrome complications
Middle Aged
Obesity complications
Obesity diet therapy
Orlistat
Overweight complications
Overweight diet therapy
Overweight drug therapy
Anti-Obesity Agents administration & dosage
Fenofibrate administration & dosage
Hypolipidemic Agents administration & dosage
Lactones administration & dosage
Lipoproteins, HDL blood
Obesity drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1463-1326
- Volume :
- 10
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Diabetes, obesity & metabolism
- Publication Type :
- Academic Journal
- Accession number :
- 17459096
- Full Text :
- https://doi.org/10.1111/j.1463-1326.2007.00733.x